Business Description
CASI Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US14757U1097
Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.45 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 0.88 | |||||
| Debt-to-EBITDA | -0.84 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -11.95 | |||||
| Beneish M-Score | -5.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.8 | |||||
| 3-Year EBITDA Growth Rate | 17.2 | |||||
| 3-Year EPS without NRI Growth Rate | 15 | |||||
| 3-Year FCF Growth Rate | 26 | |||||
| 3-Year Book Growth Rate | -35 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.39 | |||||
| 9-Day RSI | 29.61 | |||||
| 14-Day RSI | 29.58 | |||||
| 6-1 Month Momentum % | -10.21 | |||||
| 12-1 Month Momentum % | 0.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.55 | |||||
| Quick Ratio | 2.6 | |||||
| Cash Ratio | 1.84 | |||||
| Days Inventory | 249.07 | |||||
| Days Sales Outstanding | 124.58 | |||||
| Days Payable | 81.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.6 | |||||
| Shareholder Yield % | -60.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.19 | |||||
| Operating Margin % | -74.62 | |||||
| Net Margin % | -79.51 | |||||
| FCF Margin % | -12.6 | |||||
| ROE % | -79.54 | |||||
| ROA % | -32.69 | |||||
| ROIC % | -86.03 | |||||
| ROC (Joel Greenblatt) % | -118.6 | |||||
| ROCE % | -37.12 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.96 | |||||
| PB Ratio | 1.34 | |||||
| Price-to-Tangible-Book | 1.45 | |||||
| EV-to-EBIT | -0.84 | |||||
| EV-to-EBITDA | -0.84 | |||||
| EV-to-Revenue | 0.63 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -4.99 | |||||
| Price-to-Net-Current-Asset-Value | 3.9 | |||||
| Earnings Yield (Greenblatt) % | -119.05 | |||||
| FCF Yield % | -13.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CASI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CASI Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 33.879 | ||
| EPS (TTM) ($) | -2.03 | ||
| Beta | 0.69 | ||
| Volatility % | 89.41 | ||
| 14-Day RSI | 29.58 | ||
| 14-Day ATR ($) | 0.283788 | ||
| 20-Day SMA ($) | 2.813 | ||
| 12-1 Month Momentum % | 0.67 | ||
| 52-Week Range ($) | 1.85 - 8.48 | ||
| Shares Outstanding (Mil) | 13.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CASI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CASI Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CASI Pharmaceuticals Inc Frequently Asked Questions
What is CASI Pharmaceuticals Inc(CASI)'s stock price today?
The current price of CASI is $2.42. The 52 week high of CASI is $8.48 and 52 week low is $1.85.
When is next earnings date of CASI Pharmaceuticals Inc(CASI)?
The next earnings date of CASI Pharmaceuticals Inc(CASI) is 2024-05-20.
Does CASI Pharmaceuticals Inc(CASI) pay dividends? If so, how much?
CASI Pharmaceuticals Inc(CASI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers